Tracleer licence extension

The licence for Tracleer (bosentan) has been extended to include use for the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Treatment should be initiated at a dose of 62.5mg twice daily for four weeks and then increased to a maintenance dose of 125mg twice daily.

View Tracleer drug record

Further information: Actelion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more